OBJECTIVE: To determine morphological and biological control as well as toxicity and quality of life (QoL) of men with localized prostate cancer (PCa) treated with MRI-guided focal boost radiotherapy. MATERIAL AND METHODS: 30 patients with PCa and a visible dominant intraprostatic lesion (DIL) identified on mpMRI were included in a prospective Phase II trial. Matching point registration of planning CT and T2W, diffusion-weighted and a gradient-recalled echo (GRE) MRI images made in treatment position was used for prostate and tumour delineation. Treatment consisted on 35 daily fractions of 2.17 Gy with a concomitant focal boost to the DIL of 2.43 Gy using volumetric modulated arc therapy (VMAT) and image-guided radiation therapy (IGRT) with intraprostatic fiducial markers. Biochemical failure was analysed using PSA nadir +2 ng/mL criteria and local control using mpMRI evaluation at 6-9 months following RT. Acute and late toxicity were defined according to CTCAE v.4.0 and RTOG/EORTC scales and QoL was assessed using IPSS, EPIC short-form and UCLA-PCI questionnaires. RESULTS: The median radiation dose to the prostate was 77.6 Gy (IQR 77.3-78.1), and to the DIL was 85.5 Gy (IQR 85.0-86.0). With a median follow up of 30.0 months (IQR 25.5-40.27), all patients remain free of biochemical relapse. An mpMRI complete response was observed in 25 patients during the first post-treatment evaluation at 6 months. The remaining five patients achieved a complete disappearance of the DIL both on T2 and DWI on the second mpMRI performed at 9 months following treatment. Six out of 30 (20%) patients presented acute Grade 2 urinary toxicity with no Grade 3 acute complications. Acute rectal toxicity was only found in 2 (6.6%) patients (both Grade 1). Only late Grade 1 urinary and rectal complications were observed in 3/30 patients, respectively, with no Grade 2 or more late toxicity. The urinary, bowel and sexual bother EPIC scores were slightly and insignificantly increased in the first 3 months post-treatment, returning to normal afterwards. CONCLUSIONS: mpMRI-guided focal boost using VMAT hypofractionated technique is associated with an excellent morphological and functional response control and a safe toxicity profile. ADVANCES IN KNOWLEDGE: In the present trial, we examined the potential role of mpMRI for radiological assessment (functional and morphological) of treatment response in high-risk prostate cancer patients treated with MRI-guided focal radiotherapy dose intensification to dominant Intraprostatic lesion.
OBJECTIVE: To determine morphological and biological control as well as toxicity and quality of life (QoL) of men with localized prostate cancer (PCa) treated with MRI-guided focal boost radiotherapy. MATERIAL AND METHODS: 30 patients with PCa and a visible dominant intraprostatic lesion (DIL) identified on mpMRI were included in a prospective Phase II trial. Matching point registration of planning CT and T2W, diffusion-weighted and a gradient-recalled echo (GRE) MRI images made in treatment position was used for prostate and tumour delineation. Treatment consisted on 35 daily fractions of 2.17 Gy with a concomitant focal boost to the DIL of 2.43 Gy using volumetric modulated arc therapy (VMAT) and image-guided radiation therapy (IGRT) with intraprostatic fiducial markers. Biochemical failure was analysed using PSA nadir +2 ng/mL criteria and local control using mpMRI evaluation at 6-9 months following RT. Acute and late toxicity were defined according to CTCAE v.4.0 and RTOG/EORTC scales and QoL was assessed using IPSS, EPIC short-form and UCLA-PCI questionnaires. RESULTS: The median radiation dose to the prostate was 77.6 Gy (IQR 77.3-78.1), and to the DIL was 85.5 Gy (IQR 85.0-86.0). With a median follow up of 30.0 months (IQR 25.5-40.27), all patients remain free of biochemical relapse. An mpMRI complete response was observed in 25 patients during the first post-treatment evaluation at 6 months. The remaining five patients achieved a complete disappearance of the DIL both on T2 and DWI on the second mpMRI performed at 9 months following treatment. Six out of 30 (20%) patients presented acute Grade 2 urinary toxicity with no Grade 3 acute complications. Acute rectal toxicity was only found in 2 (6.6%) patients (both Grade 1). Only late Grade 1 urinary and rectal complications were observed in 3/30 patients, respectively, with no Grade 2 or more late toxicity. The urinary, bowel and sexual bother EPIC scores were slightly and insignificantly increased in the first 3 months post-treatment, returning to normal afterwards. CONCLUSIONS: mpMRI-guided focal boost using VMAT hypofractionated technique is associated with an excellent morphological and functional response control and a safe toxicity profile. ADVANCES IN KNOWLEDGE: In the present trial, we examined the potential role of mpMRI for radiological assessment (functional and morphological) of treatment response in high-risk prostate cancer patients treated with MRI-guided focal radiotherapy dose intensification to dominant Intraprostatic lesion.
Authors: Peter Steenbergen; Karin Haustermans; Evelyne Lerut; Raymond Oyen; Liesbeth De Wever; Laura Van den Bergh; Linda G W Kerkmeijer; Frank A Pameijer; Wouter B Veldhuis; Jochem R N van der Voort van Zyp; Floris J Pos; Stijn W Heijmink; Robin Kalisvaart; Hendrik J Teertstra; Cuong V Dinh; Ghazaleh Ghobadi; Uulke A van der Heide Journal: Radiother Oncol Date: 2015-04-29 Impact factor: 6.280
Authors: Yasir Alayed; Melanie Davidson; Stanley Liu; William Chu; Eric Tseng; Patrick Cheung; Danny Vesprini; Hans Cheung; Gerard Morton; H B Musunuru; Anath Ravi; Renee Korol; Andrea Deabreu; Ling Ho; Kristina Commisso; Zeeba Bhounr; Laura D'Alimonte; Nicole Mittmann; Alice Dragomir; Liang Zhang; Andrew Loblaw Journal: Int J Radiat Oncol Biol Phys Date: 2020-01-25 Impact factor: 7.038
Authors: Carl Salembier; Geert Villeirs; Berardino De Bari; Peter Hoskin; Bradley R Pieters; Marco Van Vulpen; Vincent Khoo; Ann Henry; Alberto Bossi; Gert De Meerleer; Valérie Fonteyne Journal: Radiother Oncol Date: 2018-04 Impact factor: 6.280
Authors: A Zapatero; M Adrados; L Torres; M S Talaya; A Cruz Conde; C Martin de Vidales; L Vega Piris; C Olivier; M T Murillo Journal: Rep Pract Oncol Radiother Date: 2019-12-09
Authors: Francesco Cuccia; Stefanie Corradini; Rosario Mazzola; Luigi Spiazzi; Michele Rigo; Marco Lorenzo Bonù; Ruggero Ruggieri; Michela Buglione di Monale E Bastia; Stefano Maria Magrini; Filippo Alongi Journal: Cancers (Basel) Date: 2021-04-09 Impact factor: 6.639